Global Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) Pipeline Review, H2 2020 Featuring ALSP, Aviex Technologies, Phelix Therapeutics, & Virobay – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Cathepsin B – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
The latest report Cathepsin B – Pipeline Review, H2 2020, outlays comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) – Cathepsin B (CatB) is an enzymatic protein belonging to the peptidase. It promotes hydrolysis of proteins with broad specificity for peptide bonds.
It cleaves -Arg-Arg- – -Xaa bonds in small molecule substrates. In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides. The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 3 and 2 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Infectious Disease, Gastrointestinal and Immunology which include indications Alzheimer’s Disease, Autoimmune Disorders, Cancer Pain, Ebolavirus Infections (Ebola Hemorrhagic Fever), Glioblastoma Multiforme (GBM), Liver Fibrosis, Neuropathic Pain (Neuralgia), Pancreatic Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Schistosomiasis mansoni Infections and Traumatic Brain Injury.
Furthermore, this report also reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics development with respective active and dormant or discontinued projects.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)
- The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics
Key Topics Covered:
Introduction
- Report Coverage
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) – Overview
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) – Companies Involved in Therapeutics Development
- ALSP Inc
- Aviex Technologies LLC
- Phelix Therapeutics LLC
- Virobay Inc
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) – Drug Profiles
ALP-496 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
AV-0213W – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
CIBP-4 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Drugs to Inhibit Cathepsin B for Ebola Viral Infections – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Small Molecule to Inhibit Cathepsin B for Oncology – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Small Molecules to Inhibit Cathepsin B for Alzheimer’s Disease – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
VBY-285 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
VBY-825 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) – Dormant Products
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) – Product Development Milestones
- Featured News & Press Releases
- Apr 19, 2016: American Life Science Pharmaceuticals Obtains Patent
- Jan 25, 2016: ALSP invited to Give Oral Presentation at the Keystone TBI Conference January 25-27 in Santa Fe, New Mexico
- Nov 14, 2011: Virobay’s Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
Appendix
Companies Mentioned
- ALSP Inc
- Aviex Technologies LLC
- Phelix Therapeutics LLC
- Virobay Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/97g5ul
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900